Abstract:BACKGROUND: This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study.METHODS: This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 × 1011 viral particles per mL or 5 × 1010 viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days. All recruited participants who received at least one dose were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, NCT04341389.FINDINGS: 603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020. 508 eligible participants (50% male; mean age 39·7 years, SD 12·5) consented to participate in the trial and were randomly assigned to receive the vaccine (1 × 1011 viral particles n=253; 5 × 1010 viral particles n=129) or placebo (n=126). In the 1 × 1011 and 5 × 1010 viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656·5 (95% CI 575·2-749·2) and 571·0 (467·6-697·3), with seroconversion rates at 96% (95% CI 93-98) and 97% (92-99), respectively, at day 28. Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8-22·7) and 18·3 (14·4-23·3) in participants receiving 1 × 1011 and 5 × 1010 viral particles, respectively. Specific interferon γ enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85-93) of 253 and 113 (88%, 81-92) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Severe adverse reactions were reported by 24 (9%) participants in the 1 × 1011 viral particles dose group and one (1%) participant in the 5 × 1010 viral particles dose group. No serious adverse reactions were documented.INTERPRETATION: The Ad5-vectored COVID-19 vaccine at 5 × 1010 viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation.FUNDING: National Key R&D Programme of China, National Science and Technology Major Project, and CanSino Biologics.

Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double‐Blind, Dose Escalation, Placebo‐ and Positive‐Controlled, Phase 1/2 Trial

Evaluation of a recombinant tetanus toxin subunit vaccine

Single Immunization of Non-Adjuvanted Recombinant Ttfc-Mi3 Nanoparticle Vaccine Elicited a Rapid and Potent Protective Immunity Against Tetanus

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

Safety and efficacy of botulinum toxin type A made in China for treatment of post-stroke upper limb spasticity: a randomized double-blind controlled trial

Safety And Immunogenicity Of A Diphtheria, Tetanus, Acellular Pertussis And Haemophilus Influenzae Type B Combination Vaccine Compared With Separate Administration Of Licensed Equivalent Vaccines In Chinese Infants And Toddlers For Primary And Booster Immunization

A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older

The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial

Co-expression of Tetanus Toxin Fragment C in Escherichia Coli with Thioredoxin and Its Evaluation As an Effective Subunit Vaccine Candidate

A Phase II/III multicenter randomized single blind non-inferiority immunogenicity and safety study of TeddyVac™ vaccine of Human Biologicals Institute in healthy subjects of 10 years to 60 years of age

Development of a method for in vitro determination of toxicity of acellular pertussis vaccine

Characterization of Neutralizing Chimeric Heavy-Chain Antibodies Against Tetanus Toxin

Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Trial.

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials

The recombinant protein combined vaccine based on the fragment C of tetanus toxin and the cross-reacting material 197

Immunogenicity and Safety of DTaP-IPV//PRP-T Combined Vaccine in Infants in China

A Phase II/III multicenter randomized single blind non-inferiority immunogenicity and safety study of TeddyVacTM vaccine of Human Biologicals Institute in healthy subjects of 10 years to 60 years of age

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults: Randomized, Double-Blind, and Placebo-Controlled Phase 1 and Phase 2 Clinical Trials

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

[Immunogenicity and Safety of DTaP-IPV//PRP-T Combined Vaccine in Infants in China].